论文部分内容阅读
目的:对比观察多西他赛联合顺铂三周方案与每周方案治疗非小细胞肺癌临床疗效及毒副反应。方法:三周方案组(A组):多西他赛75mg/m2静滴,第1天,顺铂25mg/m2静滴,第1~3天,每3~4周重复;每周方案组(B组):多西他赛60mg静滴,第1天,40mg静滴,第8、15天,顺铂25mg/m2静滴,第1、8、15天,每4周重复。治疗2个周期评价疗效,每周期评价毒性。结果:两组共71例,无CR,三周方案组PR14例,SD13例,总有效率41.2%。每周方案组PR16例,SD14例,总有效率44.4%,两组中性粒细胞Ⅲ/Ⅳ度减少分别为70.6%和25%;非血液学毒性主要是疲劳乏力,两组分别为44.1%和19.4%。结论:多西他赛联合顺铂治疗非小细胞肺癌三周与每周治疗相比,疗效相似,但每周治疗血液学毒性反应与疲劳乏力感明显下降,耐受性好。
Objective: To observe the clinical efficacy and toxicity of docetaxel combined with cisplatin in the treatment of non-small cell lung cancer (NSCLC) with three-week and weekly regimens. Methods: Three-week protocol group (group A): Docetaxel 75 mg/m2 intravenous infusion, on the first day, cisplatin 25 mg/m2 intravenous infusion, every 1 to 3 days, repeated every 3 to 4 weeks; weekly protocol group (Group B): Docetaxel 60 mg intravenously, on the first day, 40 mg intravenously, on the 8th and 15th days, cisplatin 25 mg/m2 intravenous infusion, repeated on the 1st, 8th and 15th days every 4 weeks. The curative effect was evaluated after 2 cycles of treatment, and the toxicity was evaluated every cycle. Results: There were 71 cases in the two groups, no CR, 14 cases of PR in the three-week plan group, and 13 cases of SD. The total effective rate was 41.2%. Weekly regimen PR 16 cases, SD 14 cases, total effective rate 44.4%, neutrophil III/IV reduction in the two groups were 70.6% and 25%, respectively; non-hematological toxicity was mainly fatigue and fatigue, the two groups were 44.1% And 19.4%. CONCLUSIONS: Docetaxel plus cisplatin has similar efficacy in the treatment of non-small cell lung cancer for three weeks compared with weekly treatment, but the weekly treatment of hematological toxicity and fatigue sensation is significantly reduced and well tolerated.